A phase 2 study of combination therapy with irinotecan/ S-1 (IRIS) plus panitumumab as second-line chemotherapy for metastatic colorectal cancer
收藏NIAID Data Ecosystem2026-03-06 收录
官方服务：
资源简介：
Interventions: Irinotecan (100 mg/m2) and panitumumab (6 mg/kg) on days 1 and 15 and S-1 (40–60 mg according to body surface area) twice daily for 2 weeks, repeated every 4 weeks. Primary outcome(s): Completion rate of protocol therapy Study Design: Single arm Non-randomized
创建时间：
2011-01-15
